argus

Emcure Pharmaceuticals Limited

NSE: EMCUREINE168P01015₹34,979 Cr

Timeline

Time (IST)TypeMEventSrc
21 Nov, 05:52 pm—…Emcure Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Chetan Sharma as Company Secretary & Compliance Officer of the company w.e.f. November 24, 2025.nse
19 Nov, 11:08 am—…Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentationnse
19 Nov, 11:07 am—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
18 Nov, 03:03 pm—…Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of receipt of No-objection Letter for reclassification of shareholding from Promoter and Promoter Group category to Public category, in accordance with Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015'.nse
17 Nov, 04:38 pm—…Emcure Pharmaceuticals Limited has informed the Exchange about Transcriptnse
17 Nov, 04:36 pm—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
11 Nov, 05:06 pm—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
11 Nov, 05:04 pm—…Emcure Pharmaceuticals Limited has informed the Exchange about Link of Recordingnse
11 Nov, 01:39 pm—…Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Outcome for Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Half-Year Ended September 30, 2025bse
11 Nov, 01:35 pm—…Emcure Pharmaceuticals Ltd - 544210 - Unaudited Financial Results For The Quarter And Half-Year Ended September 30, 2025bse
11 Nov, 01:30 pm—…Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
10 Nov, 11:26 am—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
10 Nov, 11:21 am—…Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2025, titled "Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra® in India as a second brand of Wegovy®".nse
03 Nov, 05:32 pm—…Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30, 2025bse
17 Oct, 06:53 pm—…Emcure Pharmaceuticals Limited has informed the Exchange about Credit Rating- Revisionnse
17 Oct, 06:48 pm—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
10 Oct, 01:43 pm—…Emcure Pharmaceuticals Limited has informed the Exchange about General Updatesnse
10 Oct, 01:42 pm—…Emcure Pharmaceuticals Ltd - 544210 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - US FDA Inspection At Our Manufacturing Facility Located At Kadu, Surendranagar, Gujarat, India.bse
08 Oct, 06:41 pm—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
08 Oct, 06:39 pm—…Emcure Pharmaceuticals Limited has informed the Exchange about Credit Ratingnse
07 Oct, 07:23 pm—…Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of withdrawal of re-classification application under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations )'.nse
06 Oct, 06:21 pm—…Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of change in email address of Registrar and Share Transfer Agent of the Company'.nse
03 Oct, 07:03 pm—…Emcure Pharmaceuticals Limited has informed the Exchange about Acquisitionnse
03 Oct, 07:01 pm—…Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Updates on Acquisitionbse
29 Sept, 07:39 pm—…Emcure Pharmaceuticals Limited has informed the Exchange regarding allotment of 56500 securities pursuant to ESOP/ESPS at its meeting held on September 29, 2025nse